Q1 2020 Hansa Biopharma AB Earnings Call Transcript
Ladies and gentlemen, welcome to the Hansa Biopharma AB Interim Report for January through March 2020. (Operator Instructions) Today, I am pleased to present CEO, Søren Tulstrup. Speakers, please begin.
¸ - ()-
Thank you, operator. Good afternoon to those of you in Europe and good morning to those in the U.S. Welcome to the Hansa Biopharma Conference Call to discuss the first quarter results for 2020. I'm Søren Tulstrup, CEO of Hansa Biopharma. With me today, I have our CFO, Donato Spota; as well as our Head of Investor Relations, Klaus Sindahl. Today, we'll review the overall progress and highlights of the business as well as the near-term milestones. Our presentation should take about 15 minutes. And after that, we'll take your questions.
Now please turn to Slide 2. Please allow me to draw your attention to our forward-looking statements, which apply to this presentation.
Please turn to Slide 3. Hansa Biopharma's strategy to transform the organization
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |